HIV testing services
Policy Brief
November 2018
WHO/CDS/HIV/18.48
The objectives of the research presented in this report were to identify case studies of community-led HIV-related health and social inclusion service delivery organizations in eastern and southern Africa; describe the typologies of the services provided; and identify evidence of their service deliv...ery and contribution beyond HIV, including advancing universal health coverage.
more
Government Barriers to Condom Use by Men Who Have Sex With Men
An analysis from the perspective of the health sector in Latin America and the Caribbean
Washington, D.C., 2017
ECDC MISSION REPORT 19–21 September 2016 ; 14–15 November 2016
Tokar A, et al. Sex Transm Infect 2019;95:193–200. doi:10.1136/sextrans-2018-053684
Supplement to the Healthcare Waste Management Toolkit for Global Fund
Practitioners and Policy Makers
R4D conducted a thorough desk review and qualitative fiscal space analysis, 19 interviews about financing for the three diseases and the extent of alignment between public financial management systems and health policy objectives, and a validation workshop with government officials.
Tanzania’...s disease response faces a triple transition challenge: replacing donor funding, closing the resource gap that would exist even with donor funding, and more efficiently delivering on disease response objectives.
more
October 2018
This publication was produced at the request of the United States Agency for International Development. It was prepared independently by David Lowe, David Hales, Britt Herstad, Billy Pick, Aisuluu Bolotbaeva, and Gulgun Jonboboeva.
The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection, and at community advocates responsible for promoting the best interests and care of HIV-positive adults. They should be read in conjunction with other published BHIVA ...guidelines.
The 2016 interim update to the 2015 BHIVA antiretroviral guidelines has been published online to include tenofovir-alafenamide/emtricitabine as a preferred NRTI backbone for first-line therapy. Changes were based on new data and the consensus opinion of the writing committee. All changes to the guideline are highlighted and include updates to the chronic kidney disease and bone disease sections of special populations and some small changes to managing virological failure.
The 2019 interim statement provides updated advice on treatment with two-drug regimens
more